Alaunos Therapeutics Inc

CEO insider buy at Alaunos Therapeutics signals confidence in the company’s promising metabolic therapy, but investors must weigh clinical and regulatory risks.

Insider buying spurs confidence as the company’s TCR‑T cell therapy pushes toward IND approval, hinting at a future share price rebound.